Business
Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy Blocker
Executed in accordance with FDA human factors and usability engineering guidance, the study is intended to de-risk downstream regulatory review and support a streamlined path toward clinical development Raanana, Israel, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced the initiation of a key usability (Human Factors) study program for its lead prod
About this update from Polyrizon Ltd.
[{"type":"text","content":"Executed in accordance with FDA human factors and usability engineering guidance, the study is intended to de-risk downstream regulatory review and support a streamlined path toward clinical development","length":202,"tagName":"p"},{"type":"text","content":"Raanana, Israel, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced the initiation of a key usability (Human Factors) study program for its lead product candidate, NASARIX™, an innovative intranasal allergy blocker designed for broad consumer use.","length":395,"tagName":"p"},{"type":"text","content":"The study marks an important value-inflection milestone in Polyrizon’s development roadmap and is being conducted to confirm alignment with U.S. Food and Drug Administration (FDA) requirements for critical product elements, including labeling, instructions for use, and overall user interaction. Executed in accordance with FDA human factors and usability engineering guidance, the study is intended to de-risk downstream regulatory review and support a streamlined path toward clinical development.","length":499,"tagName":"p"},{"type":"text","content":"Successful completion of the usability program will potentially provide essential regulatory evidence supporting NASARIX™ readiness for clinical evaluation. This milestone represents an important step toward the planned initiation of Polyrizon’s clinical trials, which are expected to commence in Q3 2026, positioning the company for continued advancement along its regulatory and potential commercialization strategy.","length":418,"tagName":"p"},{"type":"text","content":"“This usability study is a key milestone in advancing NASARIX™ toward clinical trials, which are expected to commence in Q3 2026,” said Tomer Izraeli, CEO of Polyrizon. “It underscores our commitment to FDA-aligned development, patient safety, and user-centered intranasal solutions.”","length":284,"tagName":"p"},{"type":"text","content":"About Polyrizon","length":15,"tagName":"p"},{"type":"text","content":"Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in ...